BKR is down -5.23% during regular trading, falling to about $60.31 from a prior close of $63.64. The selloff tracked crude oil dropping to its lowest since the start of the Iran conflict, as tankers resumed Strait of Hormuz transit and U.S.-Iran signaled de-escalation progress.

VRT is down -5.24% in regular trading, near $249 versus a prior-session close of $262.89, extending yesterday's -9.6% slide. The drop reflects follow-through profit-taking and a valuation reset across AI-infrastructure names, with no new company-specific filing driving the move.

ATNM is up +8.94% intraday, trading near $1.34 versus a prior close of $1.23, with the move occurring during regular market hours. The gain extends a multi-day rally following positive Phase 3 SIERRA data for Iomab-B in relapsed/refractory AML, which met its primary endpoint of durable complete remission.

LRCX is down -5.12% to roughly $299.66 in regular trading, versus a prior close of $315.84. Primary catalyst: Kioxia CEO Hiroo Ota said memory prices have "risen enough," warning further hikes could curb AI investment—spooking memory and chip-equipment names.

INTC closed up +1.69% to $106.24 during regular trading, extending the prior session's +9.05% surge to $104.47. Buying followed reports Intel may raise PC CPU prices roughly 10% in October, a third 2026 hike signaling pricing power amid chip shortages.

NAVN is down -20.93% today, sliding from a $25.89 prior close to about $20.47 intraday, extending a sharp post-earnings selloff. The decline began after-hours on Sept. 9, when shares fell roughly -15% following Navan's fiscal Q2 2027 results, and continued into the regular session.

COO is down -15.5% to roughly $53.64, extending a -6.2% drop in Wednesday's regular session after reporting fiscal Q3 results after the close. The primary catalyst was a Q3 revenue miss ($1.066B vs. ~$1.098B consensus) driven by CooperVision's U.S. channel inventory destocking.

Ondas Holdings (ONDS) shares fell roughly 25% over the trailing 30 days, sliding from a closing price of about $9.74 on August 11 to $7.29 on September 9, 2026. The decline unfolded despite record second-quarter revenue of $83.8 million (up more than 13x year over year) and an increase in full-year guidance to $525–$550 million.

Carpenter Technology (CRS) shares fell about 18.1% over the trailing 30 days, from roughly $559.75 on August 10 to $458.45 at the September 9 close, despite record fiscal fourth-quarter results. The decline followed the company's fiscal Q4 2026 report, which beat on earnings per share ($3.23 versus the $3.08 consensus) but posted revenue of $851.0 million, slightly below the $863.3 million estimate.

Credo Technology (CRDO) declined roughly 32% over the 30 days ending in early September 2026, despite delivering record quarterly results. The selloff followed a "beat-and-raise" fiscal Q1 2027 report, as investors focused on narrowing margins and heavy customer concentration rather than surging revenue.

TJX shares fell roughly 19% over the trailing 30 days, from about $155.74 to $126.12, extending a decline from the stock's June peak near $170. The selloff was triggered by the fiscal 2027 second-quarter earnings report released August 19, when near-term third-quarter guidance landed below analyst expectations.

RKLB fell roughly 21% over the last 30 days, from about $80 to the low-$60s, extending a multi-month pullback from its 52-week high. The decline came even as the company reported record second-quarter revenue of $234.1 million, up 62% year over year, and a record $2.36 billion backlog.

The central question is whether Summit Therapeutics (SMMT) can reclaim the $30 level, roughly 71% above its recent price near $17.54. The strongest bullish case rests on ivonescimab, a Phase III oncology drug candidate with a pivotal lung cancer readout expected in the second half of 2026.

Chime Financial (CHYM) trades near $34.55, up roughly 9% over the trailing 30 days, extending a ~44% August surge that followed its second-quarter earnings report. Q2 2026 revenue rose 27% year over year to $670 million, while EPS of $0.07 beat the consensus estimate of -$0.01.

Hecla Mining (NYSE: HL ) traded near $20.85 recently, leaving a roughly 44% climb required to reach the widely discussed $30 price target. The stock's 52-week high of $34.17, set in January 2026, shows $30 is an achievable level the shares have already visited during a strong silver rally.

KORU advanced roughly +72% over the trailing 30 days, rebounding sharply from a mid-summer trough as South Korean equities recovered. The fund remains down approximately -62% over the trailing three months, reflecting the extreme two-way volatility of daily 3x leverage.

The Tradr 2X Long BE Daily ETF gained roughly 51% over the trailing 30 days, rebounding from a July trough near $15 to about $22.62. The move mirrors a strong recovery in its sole underlying exposure, Bloom Energy Corp. (BE) , which advanced about 29% over the same stretch.

MSTY gained roughly 15% over the trailing 30 days, climbing from about $12.51 to $14.40 as its underlying, MSTR , rebounded sharply. The fund remains down roughly 26% over the trailing three months, reflecting a steep June drawdown in MSTR that the synthetic covered-call strategy largely mirrored on the downside.

HOOW advanced roughly 14% over the trailing 30 days, rebounding from a late-July trough to finish near $28.90. The fund is an actively managed, non-diversified ETF (exchange-traded fund) that targets approximately 1.2x (120%) the weekly total return of Robinhood Markets ( HOOD ) while paying weekly distributions.

RAM is a leveraged ETF (exchange-traded fund) that seeks 200% of the daily return of the Roundhill Memory ETF (DRAM), a concentrated basket of global memory-chip makers. The fund launched in June 2026 and is engineered for short-term traders, with daily reset mechanics that can compound losses over multi-day holding periods.